Mark Jeffrey DeLong - 29 Jan 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Business & Strat Officer
Signature
/s/ David Watson, attorney-in-fact for Mark DeLong
Issuer symbol
APLS
Transactions as of
29 Jan 2024
Net transactions value
-$23,539
Form type
4
Filing time
31 Jan 2024, 16:18:50 UTC
Previous filing
23 Jan 2024
Next filing
13 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale $23,539 -367 -0.56% $64.14 65,203 29 Jan 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/26/2024.